In summary, Exenatide and long-acting GLP-1R agonists have been demonstrated to mitigate PD in both preclinical models and recent human clinical trials via multiple GLP-1R mediated mechanisms [19, 68, 85–87]. Here, GLP1R is linked to Parkinson disease.